Acute Bilateral Parotitis Occurring during Venlafaxine Titration in an Adolescent Female with Major Depression

U. Bonnet; Y. Khalil-Boutros

doi:10.1055/s-0033-1361174

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2014; 47(01): 36-38
DOI: 10.1055/s-0033-1361174

Letter

Acute Bilateral Parotitis Occurring during Venlafaxine Titration in an Adolescent Female with Major Depression

U. Bonnet

¹Department of Psychiatry, Psychotherapy and Psychosomatics, Evangelisches Krankenhaus Castrop-Rauxel, Academic Teaching Hospital of the University of Duisburg/Essen, Germany

,

Y. Khalil-Boutros

¹Department of Psychiatry, Psychotherapy and Psychosomatics, Evangelisches Krankenhaus Castrop-Rauxel, Academic Teaching Hospital of the University of Duisburg/Essen, Germany

› Author Affiliations

Abstract

Parotitis is a fairly uncommon adverse drug reaction of psychopharmacological treatment. Here, we report on an acute bilateral parotitis, which was associated with titration of venlafaxine in a 20-year-old female suffering from a severe depressive episode. The parotitis recovered quickly with oral penicillin and was most likely caused by bacteria assumed to spread from oral flora into Stensen’s duct as a complication of pronounced venlafaxine-induced xerostomia.

Key words

bilateral parotitis - depression - venlafaxine - xerostomia - penicillin

Full Text

References

References
1 Brooks KG, Thompson DF. A review and assessment of drug-induced parotitis. Ann Pharmacother 2012; 46: 1688-1699
2 Rosen DH. Acute parotitis associated with depression and psychoactive drug therapy. Compreh Psychiat 1973; 14: 183-188
3 Ponte CD. A suspected case of trimipramine-induced salivary adenitis. Drug Intell Clin Pharm 1982; 16: 248-249
4 Lundeberg D. Nonneoplastic disorders of parotid gland. West J Med 1983; 138: 589-595
5 Szabadi E, Tavernor S. Hypo- and hypersalivation induced by psychoactive drugs. Incidence, mechanisms and therapeutical implications. CNS Drugs 1999; 11: 449-466
6 Watt J. Benign parotid swellings: a review. Proc R Soc Med 1977; 70: 483-486
7 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiat 1960; 23: 56-62
8 Hiemke C, Baumann P, Bergemann N et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011 44: 195-235
9 Norder Grusell E, Dahlén G, Ruth M et al. Bacterial flora of the human oral cavity, and the upper and lower esophagus. Dis Esophagus 2013; 26: 84-90
10 de Almeida P, del V, Grégio AM et al. Effects of antidepressants and benzodiazepines on stimulated salivary flow rate and biochemistry composition of the saliva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106: 58-65
11 Hunter KD, Wilson WS. The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Arch Oral Biol 1995; 40: 983-989
12 Garret JR. The innervation of normal human submandibular and parotid salivary glands. Demonstrated by cholinesterase histochemistry, catecholamine fluorescence and electron microscopy. Arch Oral Biol 1967; 12: 1417-1436
13 De Montigny C, Silverstone PH, Debonnel G et al. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999; 19: 401-406
14 Roseboom PH, Kalin NH. Neuropharmacology of venlafaxine. Depress Anxiety 2000; 12 (Suppl. 01) 20-29
15 Demling J, Beyer S, Kornhuber J. To sweat or not to sweat? A hypothesis on the effects of venlafaxine and SSRIs. Med Hypotheses 2010; 74: 155-157
16 Chodorowski Z. Cappuccino coffee treatment of xerostomia in patients taking tricyclic antidepressants: preliminary report. Przegl Lek 2002; 59: 392-393
17 Nierenberg AA, Greist JH, Mallinckrodt CH et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007; 23: 401-416